NASDAQ:XLRN - Acceleron Pharma Stock Price, Price Target & More

$35.42 -0.52 (-1.45 %)

(As of 04/24/2018 04:00 PM ET)

Previous Close$35.42

Today's Range$35.10 - $36.39

52-Week Range$24.37 - $46.93

Volume242,664 shs

Average Volume302,914 shs

Market Capitalization$1.63 billion

P/E Ratio-13.22

Dividend YieldN/A

Beta1.43

About Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. The company is also developing and sotatercept for the treatment of patients with pulmonary arterial hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Receive XLRN News and Ratings via Email

Sign-up to receive the latest news and ratings for XLRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:XLRN

CUSIPN/A

Webwww.acceleronpharma.com

Phone617-649-9200

Debt

Debt-to-Equity RatioN/A

Current Ratio17.04%

Quick Ratio17.04%

Price-To-Earnings

Trailing P/E Ratio-13.22

Forward P/E Ratio-14.17

P/E GrowthN/A

Sales & Book Value

Annual Sales$13.48 million

Price / Sales120.24

Cash FlowN/A

Price / CashN/A

Book Value$8.07 per share

Price / Book4.39

Profitability

EPS (Most Recent Fiscal Year)($2.68)

Net Income$-108,450,000.00

Net Margins-804.49%

Return on Equity-38.71%

Return on Assets-35.91%

Miscellaneous

Employees139

Outstanding Shares45,760,000

How to Become a New Pot Stock Millionaire

Acceleron Pharma (NASDAQ:XLRN) Frequently Asked Questions

What is Acceleron Pharma's stock symbol?

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

How were Acceleron Pharma's earnings last quarter?

Acceleron Pharma (NASDAQ:XLRN) issued its quarterly earnings data on Tuesday, February, 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by $0.02. The biopharmaceutical company had revenue of $3.71 million for the quarter, compared to the consensus estimate of $3.39 million. Acceleron Pharma had a negative return on equity of 38.71% and a negative net margin of 804.49%. View Acceleron Pharma's Earnings History.

When is Acceleron Pharma's next earnings date?

Acceleron Pharma is scheduled to release their next quarterly earnings announcement on Monday, May, 14th 2018. View Earnings Estimates for Acceleron Pharma.

What price target have analysts set for XLRN?

16 equities research analysts have issued 12 month target prices for Acceleron Pharma's shares. Their predictions range from $20.00 to $63.00. On average, they expect Acceleron Pharma's share price to reach $47.7333 in the next year. View Analyst Ratings for Acceleron Pharma.

What are Wall Street analysts saying about Acceleron Pharma stock?

Here are some recent quotes from research analysts about Acceleron Pharma stock:

1. Cann analysts commented, "Acceleron announced today preliminary results from the first two cohorts in Part 1 of the phase II clinical study of ACE-083 in patients with facioscapulohumeral dystrophy (FSHD). Results from the tibialis anterior cohort demonstrated patients treated with ACE-083 generated a mean total muscle volume increase of 12.6%; this was associated with a mean improvement in muscle fat fraction of 5.3%. Results from the biceps brachii cohort of the studyl demonstrated patients treated with ACE-083 generated a mean total muscle volume gain of 13.2%; this was associated with a mean improvement in muscle fat fraction of 0.6%." (1/8/2018)
2. According to Zacks Investment Research, "Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts. " (8/9/2017)

Who are some of Acceleron Pharma's key competitors?

Some companies that are related to Acceleron Pharma include Bio-Techne (TECH), Spark Therapeutics (ONCE), arGEN-X BV (ARGX), China Biologic Products (CBPO), Halozyme (HALO), CRISPR Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Sangamo Therapeutics (SGMO), Repligen (RGEN), Editas Medicine (EDIT), Momenta Pharmaceuticals (MNTA), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD) and DBV Technologies (DBVT).

Who are Acceleron Pharma's key executives?

Acceleron Pharma's management team includes the folowing people:

Mr. Habib J. Dable, CEO, Pres & Director (Age 49)
Dr. Thomas P. Maniatis, Co-Founder, Member of Scientific Advisory Board & Director (Age 75)
Mr. Kevin F. McLaughlin, CFO, Sr. VP, Treasurer & Principal Accounting Officer (Age 62)
Dr. Ravindra Kumar Ph.D., Chief Scientific Officer and Sr. VP (Age 58)
Dr. Matthew L. Sherman, Chief Medical Officer & Exec. VP (Age 62)

Has Acceleron Pharma been receiving favorable news coverage?

News headlines about XLRN stock have been trending somewhat positive recently, Accern reports. The research firm ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Acceleron Pharma earned a media sentiment score of 0.15 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 45.79 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Acceleron Pharma?

Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acceleron Pharma's stock price today?

One share of XLRN stock can currently be purchased for approximately $35.42.

How big of a company is Acceleron Pharma?

Acceleron Pharma has a market capitalization of $1.63 billion and generates $13.48 million in revenue each year. The biopharmaceutical company earns $-108,450,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Acceleron Pharma employs 139 workers across the globe.

How can I contact Acceleron Pharma?

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]

MarketBeat Community Rating for Acceleron Pharma (XLRN)

Community Ranking:		3.1 out of 5 ( )
Outperform Votes:		317 (Vote Outperform)
Underperform Votes:		189 (Vote Underperform)
Total Votes:		506

MarketBeat's community ratings are surveys of what our community members think about Acceleron Pharma and other stocks. Vote "Outperform" if you believe XLRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XLRN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Acceleron Pharma (NASDAQ:XLRN) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

16 Wall Street analysts have issued ratings and price targets for Acceleron Pharma in the last 12 months. Their average twelve-month price target is $47.7333, suggesting that the stock has a possible upside of 34.76%. The high price target for XLRN is $63.00 and the low price target for XLRN is $20.00. There are currently 1 sell rating, 4 hold ratings and 11 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.63	2.63	2.59	2.61
Ratings Breakdown:	1 Sell Rating(s) 4 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 4 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 5 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 5 Hold Rating(s) 12 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$47.7333	$47.7333	$45.3333	$44.0625
Price Target Upside:	34.76% upside	17.54% upside	0.76% upside	13.68% upside

Acceleron Pharma (NASDAQ:XLRN) Consensus Price Target History

Price Target History for Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma (NASDAQ:XLRN) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/2/2018	Credit Suisse Group	Reiterated Rating	Buy	$55.00	High
3/1/2018	Citigroup	Boost Price Target	Buy -> Positive	$44.00 -> $63.00	High
2/28/2018	Barclays	Boost Price Target	Overweight -> Overweight	$50.00 -> $54.00	High
2/28/2018	HC Wainwright	Reiterated Rating	Buy	$62.00	High
2/28/2018	Piper Jaffray	Boost Price Target	Overweight	$53.00	High
2/26/2018	JPMorgan Chase	Upgrade	Neutral -> Overweight	$33.00	High
1/8/2018	Cann	Reiterated Rating	Hold		High
1/8/2018	Oppenheimer	Reiterated Rating	Hold		Medium
11/2/2017	Royal Bank of Canada	Reiterated Rating	Hold		N/A
9/12/2017	UBS	Reiterated Rating	Buy	$36.00 -> $50.00	High
6/14/2017	Instinet	Reiterated Rating	Buy	$58.00	Low
6/13/2017	FBR & Co	Set Price Target	Buy	$63.00	High
6/13/2017	Morgan Stanley	Lower Price Target	Overweight	$51.00 -> $42.00	High
6/13/2017	CIBC	Downgrade	Outperform -> Market Perform		Low
5/17/2017	Goldman Sachs	Initiated Coverage	Sell -> Sell	$20.00	High
5/1/2017	JMP Securities	Reiterated Rating	Outperform	$39.00	Low
3/1/2017	Nomura	Initiated Coverage	Buy		N/A
12/1/2016	Leerink Swann	Set Price Target	Buy	$50.00	N/A
8/19/2016	BTIG Research	Initiated Coverage	Buy	$46.00	N/A

(Data available from 4/24/2016 forward)

Acceleron Pharma (NASDAQ:XLRN) Earnings History and Estimates Chart

Earnings by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma (NASDAQ:XLRN) Earnings Estimates

2018 EPS Consensus Estimate: ($2.35)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	($0.62)	($0.62)	($0.62)
Q2 2018	2	($0.68)	($0.59)	($0.64)
Q3 2018	2	($0.55)	($0.26)	($0.41)
Q4 2018	2	($0.89)	($0.49)	($0.69)

Acceleron Pharma (NASDAQ XLRN) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/7/2018		($0.62)					N/A
2/27/2018	Q4 2017	($0.60)	($0.6180)	$3.39 million	$3.71 million	View	Listen
11/7/2017	Q3 2017	($0.67)	($0.65)	$3.52 million	$3.00 million	View	N/A
8/3/2017	Q2 2017	($0.65)	($0.77)	$3.69 million	$3.10 million	View	Listen
5/8/2017	3/31/2017	($0.58)	($0.66)	$3.38 million	$3.71 million	View	Listen
3/1/2017	Q416	($0.55)	($0.51)	$3.74 million	$3.37 million	View	Listen
11/3/2016	Q316	($0.53)	($0.55)	$4.08 million	$3.00 million	View	Listen
8/4/2016	Q216	($0.50)	($0.59)	$3.77 million	$3.20 million	View	Listen
5/5/2016	Q116	($0.26)	$0.14	$8.70 million	$18.20 million	View	Listen
2/25/2016	Q415	($0.09)	($0.81)	$15.70 million	$3.80 million	View	Listen
11/4/2015	Q315	($0.46)	($0.36)	$4.38 million	$4.16 million	View	Listen
8/6/2015	Q215	($0.49)	($0.32)	$4.23 million	$5.72 million	View	Listen
5/7/2015		($0.43)	($0.45)	$3.98 million	$4.42 million	View	N/A
3/2/2015	Q414	($0.23)	($0.55)	$12.90 million	$3.74 million	View	Listen
11/7/2014		($0.27)	($0.25)	$17.76 million	$3.51 million	View	N/A
8/12/2014		($0.55)	($0.54)		$4.08 million	View	N/A
5/15/2014	Q114	($0.44)	($0.30)	$2.85 million	$3.31 million	View	N/A
2/26/2014	Q413	($0.08)	($0.64)	$13.66 million	$11.50 million	View	N/A
11/6/2013		($0.19)	($5.62)	$8.00 million	$4.27 million	View	N/A

(Earnings results data provided by Zacks Investment Research)

Acceleron Pharma (NASDAQ:XLRN) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Acceleron Pharma (NASDAQ XLRN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.00%
Institutional Ownership Percentage: 87.57%

Insider Trading History for Acceleron Pharma (NASDAQ:XLRN)

Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma (NASDAQ XLRN) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/3/2018	John D Quisel	SVP	Sell	1,204	$38.40	$46,233.60
4/3/2018	Kevin F Mclaughlin	CFO	Sell	4,000	$38.45	$153,800.00
4/3/2018	Matthew L Sherman	EVP	Sell	4,600	$38.43	$176,778.00
3/6/2018	Richard F Pops	Director	Sell	37,500	$41.42	$1,553,250.00	68,750
1/12/2018	Christopher Rovaldi	SVP	Sell	11,000	$45.00	$495,000.00	35,701
1/4/2018	Kevin F Mclaughlin	CFO	Sell	19,000	$42.89	$814,910.00	45,300
1/3/2018	Christopher Rovaldi	SVP	Sell	2,266	$42.42	$96,123.72	52,977
1/3/2018	Matthew L Sherman	EVP	Sell	4,633	$42.71	$197,875.43	77,700
1/2/2018	Kevin F Mclaughlin	CFO	Sell	4,000	$42.42	$169,680.00	45,300
12/15/2017	Jean George	Director	Sell	105,122	$35.73	$3,756,009.06	1,250
9/25/2017	Corp /De/ Celgene	Major Shareholder	Buy	745,592	$37.00	$27,586,904.00	6,118,479
9/13/2017	John D Quisel	SVP	Sell	5,113	$38.42	$196,441.46	57,918
9/12/2017	Christopher Rovaldi	SVP	Sell	14,000	$38.41	$537,740.00	28,232
9/12/2017	Kevin F Mclaughlin	CFO	Sell	16,000	$38.41	$614,560.00	50,810
9/12/2017	Matthew L Sherman	EVP	Sell	18,400	$38.41	$706,744.00	79,750
8/8/2017	Ravindra Kumar	SVP	Sell	13,065	$35.41	$462,631.65	108,392
7/5/2017	Kevin F Mclaughlin	CFO	Sell	34,400	$32.00	$1,100,800.00	80,950
7/5/2017	Matthew L Sherman	EVP	Sell	16,000	$32.00	$512,000.00	112,400
7/5/2017	Ravindra Kumar	SVP	Sell	937	$32.00	$29,984.00	96,264
1/4/2017	Kevin F Mclaughlin	CFO	Sell	1,700	$27.45	$46,665.00	72,200
1/4/2017	Matthew L Sherman	EVP	Sell	2,000	$27.46	$54,920.00	98,100
1/4/2017	Steven D Ertel	COO	Sell	2,500	$27.44	$68,600.00	130,977
12/30/2016	Joseph S Zakrzewski	Director	Buy	4,000	$25.50	$102,000.00	4,000
12/8/2016	Terrance Mcguire	Director	Sell	34,928	$30.96	$1,081,370.88	1,624
11/17/2016	Jean George	Director	Sell	453,505	$38.39	$17,410,056.95
10/10/2016	Ravindra Kumar	SVP	Sell	52,486	$33.92	$1,780,325.12	91,875
9/30/2016	Jean George	Director	Sell	857,145	$35.50	$30,428,647.50
9/21/2016	John D Quisel	SVP	Sell	45,952	$38.05	$1,748,473.60	77,004
9/12/2016	John D Quisel	SVP	Sell	21,438	$32.14	$689,017.32	86,723
7/6/2016	John L Knopf	CEO	Sell	100,000	$33.87	$3,387,000.00	147,106
7/5/2016	John L Knopf	CEO	Sell	30,501	$33.26	$1,014,463.26	147,106
7/5/2016	Steven D Ertel	COO	Sell	32,270	$34.56	$1,115,251.20	137,365
7/1/2016	John L Knopf	CEO	Sell	28,022	$34.72	$972,923.84	147,106
7/1/2016	Kevin F Mclaughlin	CFO	Sell	25,300	$34.66	$876,898.00	82,900
7/1/2016	Matthew L Sherman	EVP	Sell	26,000	$34.74	$903,240.00	91,500
7/1/2016	Steven D Ertel	COO	Sell	28,304	$34.77	$984,130.08	137,365
5/20/2016	John L Knopf	CEO	Sell	100,000	$33.07	$3,307,000.00	160,674
4/7/2016	Matthew L Sherman	EVP	Sell	26,000	$32.00	$832,000.00	95,524
4/7/2016	Steven D Ertel	COO	Sell	32,270	$32.00	$1,032,640.00	131,098
1/11/2016	Corp /De/ Celgene	Major Shareholder	Buy	800,000	$40.00	$32,000,000.00	5,372,887
10/15/2015	Matthew L. Sherman	EVP	Sell	6,000	$23.28	$139,680.00	91,604
10/7/2015	John L. Knopf	CEO	Sell	19,000	$24.38	$463,220.00	119,084
10/7/2015	Kevin F. Mclaughlin	CFO	Sell	7,000	$24.38	$170,660.00	80,000
9/16/2015	Matthew L. Sherman	EVP	Sell	2,000	$33.24	$66,480.00	96,404
9/15/2015	Ravindra Kumar	VP	Sell	33,000	$35.00	$1,155,000.00	56,685
9/15/2015	Steven D. Ertel	COO	Sell	2,000	$33.61	$67,220.00	119,656
9/14/2015	John D. Quisel	SVP	Sell	5,500	$33.35	$183,425.00	76,123
9/8/2015	John L. Knopf	CEO	Sell	19,000	$30.20	$573,800.00	21,584
9/8/2015	Kevin F. Mclaughlin	CFO	Sell	6,500	$30.16	$196,040.00	40,000
8/18/2015	Matthew L Sherman	EVP	Sell	7,000	$31.13	$217,910.00
8/14/2015	John D Quisel	SVP	Sell	5,500	$30.83	$169,565.00
7/20/2015	Matthew L Sherman	EVP	Sell	6,000	$32.46	$194,760.00
7/15/2015	Steven D Ertel	COO	Sell	2,000	$31.38	$62,760.00
7/14/2015	John D Quisel	SVP	Sell	5,500	$30.00	$165,000.00
7/7/2015	John L Knopf	CEO	Sell	19,000	$29.70	$564,300.00
7/7/2015	Kevin F Mclaughlin	CFO	Sell	7,000	$29.70	$207,900.00
6/18/2015	Matthew L Sherman	EVP	Sell	7,000	$31.54	$220,780.00
6/15/2015	John D Quisel	SVP	Sell	5,500	$31.13	$171,215.00
6/15/2015	Steven D Ertel	COO	Sell	2,000	$31.11	$62,220.00
6/8/2015	John L Knopf	CEO	Sell	19,000	$32.51	$617,690.00
6/8/2015	Kevin F Mclaughlin	CFO	Sell	6,500	$32.49	$211,185.00
5/18/2015	Matthew L Sherman	EVP	Sell	7,000	$32.37	$226,590.00
5/15/2015	Steven D Ertel	COO	Sell	2,000	$31.49	$62,980.00
4/20/2015	Matthew L Sherman	EVP	Sell	5,000	$33.52	$167,600.00
4/15/2015	Steven D Ertel	COO	Sell	2,000	$33.58	$67,160.00
4/7/2015	John L Knopf	CEO	Sell	20,000	$34.87	$697,400.00
4/7/2015	Kevin F Mclaughlin	CFO	Sell	7,000	$34.88	$244,160.00
3/18/2015	Matthew L Sherman	EVP	Sell	6,000	$41.18	$247,080.00
3/16/2015	John D Quisel	SVP	Sell	9,500	$41.00	$389,500.00
3/9/2015	John L Knopf	CEO	Sell	20,000	$40.25	$805,000.00
3/9/2015	Kevin F Mclaughlin	CFO	Sell	6,500	$40.25	$261,625.00
1/20/2015	Matthew L Sherman	SVP	Sell	7,000	$41.64	$291,480.00
1/15/2015	Steven D Ertel	SVP	Sell	2,000	$40.58	$81,160.00
1/12/2015	Kevin F Mclaughlin	CFO	Sell	2,000	$40.66	$81,320.00
1/12/2015	Ravindra Kumar	VP	Sell	1,500	$40.80	$61,200.00
1/7/2015	John L Knopf	CEO	Sell	20,000	$39.62	$792,400.00
1/7/2015	Kevin F Mclaughlin	CFO	Sell	5,000	$39.46	$197,300.00
1/2/2015	Ravindra Kumar	VP	Sell	4,000	$38.46	$153,840.00
1/2/2015	Steven D Ertel	SVP	Sell	5,000	$38.47	$192,350.00
12/23/2014	Edwin M Kania Jr	Director	Sell	54,350	$38.00	$2,065,300.00
12/18/2014	Matthew L Sherman	SVP	Sell	5,000	$40.16	$200,800.00
12/12/2014	John D Quisel	SVP	Sell	4,000	$41.35	$165,400.00
12/9/2014	Jean George	Director	Sell	97,407	$44.90	$4,373,574.30
12/8/2014	John L Knopf	CEO	Sell	20,000	$43.99	$879,800.00
12/8/2014	Kevin F Mclaughlin	CFO	Sell	10,000	$44.02	$440,200.00
12/8/2014	Tom Maniatis	Director	Sell	23,400	$45.00	$1,053,000.00
12/1/2014	Ravindra Kumar	VP	Sell	4,000	$35.88	$143,520.00
12/1/2014	Steven D Ertel	SVP	Sell	7,500	$35.87	$269,025.00
11/18/2014	Matthew L Sherman	SVP	Sell	5,082	$33.76	$171,568.32
11/13/2014	Ravindra Kumar	VP	Sell	16,000	$34.53	$552,480.00
10/28/2014	Tom Maniatis	Director	Sell	23,400	$35.00	$819,000.00
10/8/2014	John L Knopf	CEO	Sell	20,000	$29.71	$594,200.00
10/8/2014	Matthew L Sherman	SVP	Sell	5,082	$29.50	$149,919.00
10/7/2014	Kevin F Mclaughlin	CFO	Sell	10,000	$29.25	$292,500.00
10/1/2014	Ravindra Kumar	VP	Sell	11,000	$29.89	$328,790.00
10/1/2014	Steven D Ertel	SVP	Sell	10,000	$29.66	$296,600.00
9/30/2014	John D Quisel	SVP	Sell	7,000	$30.01	$210,070.00
9/18/2014	Matthew L Sherman	SVP	Sell	5,000	$25.48	$127,400.00
9/12/2014	John D Quisel	SVP	Sell	2,000	$25.43	$50,860.00
9/9/2014	John L Knopf	CEO	Sell	20,000	$24.46	$489,200.00
9/9/2014	Kevin F Mclaughlin	CFO	Sell	10,000	$24.48	$244,800.00
9/8/2014	John L Knopf	CEO	Sell	6,700	$24.92	$166,964.00
9/8/2014	Kevin F Mclaughlin	CFO	Sell	3,300	$24.90	$82,170.00
9/3/2014	Matthew L Sherman	SVP	Sell	5,000	$25.82	$129,100.00
8/18/2014	Matthew L Sherman	SVP	Sell	2,500	$29.62	$74,050.00
8/14/2014	John D Quisel	SVP	Sell	13,000	$29.98	$389,740.00
8/14/2014	John L Knopf	CEO	Sell	17,500	$29.78	$521,150.00
8/14/2014	Kevin F Mclaughlin	CFO	Sell	10,000	$29.78	$297,800.00
8/14/2014	Ravindra Kumar	VP	Sell	9,000	$29.97	$269,730.00
7/18/2014	Matthew L Sherman	SVP	Sell	2,500	$26.22	$65,550.00
7/14/2014	John D Quisel	SVP	Sell	5,000	$29.73	$148,650.00
7/9/2014	Matthew L Sherman	SVP	Sell	7,500	$28.99	$217,425.00
7/7/2014	John L Knopf	CEO	Sell	17,500	$31.74	$555,450.00
7/7/2014	Kevin F Mclaughlin	CFO	Sell	10,000	$31.72	$317,200.00
7/1/2014	Ravindra Kumar	VP	Sell	2,000	$34.10	$68,200.00
7/1/2014	Steven D Ertel	SVP	Sell	10,000	$34.09	$340,900.00
6/26/2014	Jean George	Director	Sell	10,491	$35.01	$367,289.91
6/24/2014	Jean George	Director	Sell	25,477	$35.16	$895,771.32
6/20/2014	Ravindra Kumar	VP	Sell	7,000	$35.00	$245,000.00
6/18/2014	Matthew L Sherman	SVP	Sell	2,500	$34.42	$86,050.00
6/13/2014	John D Quisel	VP	Sell	9,000	$33.94	$305,460.00
6/11/2014	Matthew L Sherman	SVP	Sell	7,500	$33.23	$249,225.00
6/9/2014	John L Knopf	CEO	Sell	15,000	$31.65	$474,750.00
6/9/2014	Kevin F Mclaughlin	CFO	Sell	10,000	$31.65	$316,500.00
5/19/2014	John Knopf	CEO	Sell	15,000	$31.52	$472,800.00	206,500
5/19/2014	John Quisel	VP	Sell	9,000	$31.43	$282,870.00
5/19/2014	Steven Ertel	SVP	Sell	10,000	$31.52	$315,200.00	27,656
5/5/2014	Corp /De/ Celgene	major shareholder	Buy	1,100,000	$42.86	$47,146,000.00	4,572,887
5/5/2014	Jean George	Director	Sell	215,644	$42.86	$9,242,501.84
4/24/2014	Edwin Kania, Jr.	Director	Sell	1,000,000	$32.05	$32,050,000.00	4,867
4/22/2014	Ravindra Kumar	VP	Sell	2,000	$35.86	$71,720.00	45,890
4/22/2014	Steven Ertel	SVP	Sell	2,500	$35.87	$89,675.00	27,656
1/28/2014	Corp /De/ Celgene	Major Shareholder	Buy	300,000	$50.00	$15,000,000.00
9/24/2013	Corp /De/ Celgene	Major Shareholder	Buy	666,667	$15.00	$10,000,005.00

(Data available from 1/1/2013 forward)

Acceleron Pharma (NASDAQ XLRN) News Headlines

Source:

Date	Headline
	2 Beta Thalassemia Drugs Are Fast Approaching the Finish Line finance.yahoo.com - April 22 at 8:17 AM
	Acceleron Pharma's (XLRN) Hold Rating Reaffirmed at Cann www.americanbankingnews.com - April 20 at 10:18 PM
	Acceleron Pharma (XLRN) Receives "Buy" Rating from Credit Suisse Group www.americanbankingnews.com - April 19 at 11:52 PM
	Acceleron Pharma (XLRN) Stock Rating Upgraded by BidaskClub www.americanbankingnews.com - April 19 at 9:23 AM
	Acceleron Pharma (XLRN) Downgraded by BidaskClub to "Sell" www.americanbankingnews.com - April 18 at 10:23 AM
	$4.35 Million in Sales Expected for Acceleron Pharma (XLRN) This Quarter www.americanbankingnews.com - April 18 at 2:46 AM
	Acceleron Pharma (XLRN) Expected to Post Earnings of -$0.64 Per Share www.americanbankingnews.com - April 16 at 3:14 PM
	Acceleron Pharma (XLRN) Lowered to "Hold" at Zacks Investment Research www.americanbankingnews.com - April 11 at 8:26 PM
	Q4 Biotech Catalyst Watchlist: Phase 3 Clinical Trials seekingalpha.com - April 10 at 8:25 AM
	Acceleron Pharma (XLRN) Given Consensus Recommendation of "Buy" by Brokerages www.americanbankingnews.com - April 5 at 12:10 PM
	Acceleron Pharma (XLRN) SVP John D. Quisel Sells 1,204 Shares www.americanbankingnews.com - April 4 at 11:37 PM
	Acceleron Pharma (XLRN) EVP Sells $176,778.00 in Stock www.americanbankingnews.com - April 4 at 11:16 PM
	Kevin F. Mclaughlin Sells 4,000 Shares of Acceleron Pharma (XLRN) Stock www.americanbankingnews.com - April 4 at 11:16 PM
	Acceleron Pharma (XLRN) Lifted to Buy at ValuEngine www.americanbankingnews.com - April 2 at 10:26 PM
	Acceleron Pharma (XLRN) Expected to Post Quarterly Sales of $4.35 Million www.americanbankingnews.com - April 1 at 2:36 AM
	Acceleron Pharma (XLRN) Expected to Announce Earnings of -$0.64 Per Share www.americanbankingnews.com - March 30 at 5:14 PM
	Oppenheimer Reaffirms "Hold" Rating for Acceleron Pharma (XLRN) www.americanbankingnews.com - March 30 at 12:04 PM
	Acceleron Pharma (XLRN) Cut to "Hold" at BidaskClub www.americanbankingnews.com - March 30 at 11:06 AM
	Zacks: Analysts Expect Acceleron Pharma Inc (XLRN) Will Post Quarterly Sales of $4.35 Million www.americanbankingnews.com - March 15 at 4:42 AM
	Acceleron to Host Educational Webinar with Leading Clinicians to Provide an Overview of Pulmonary Arterial Hypertension (PAH) and the Sotatercept Phase 2 Trial finance.yahoo.com - March 12 at 9:01 AM
	Acceleron Pharma Inc (XLRN) Receives Average Rating of "Buy" from Analysts www.americanbankingnews.com - March 11 at 1:18 PM
	Acceleron Pharma Inc (XLRN) Director Richard F. Pops Sells 37,500 Shares www.americanbankingnews.com - March 8 at 6:13 PM
	Acceleron Pharma Inc (XLRN) is Sectoral Asset Management Inc's 6th Largest Position www.americanbankingnews.com - March 5 at 3:35 PM
	Acceleron Pharma Inc (XLRN) Holdings Lifted by UBS Asset Management Americas Inc. www.americanbankingnews.com - March 5 at 9:42 AM
	Leerink Swann Comments on Acceleron Pharma Inc's Q2 2018 Earnings (XLRN) www.americanbankingnews.com - March 5 at 3:12 AM
	Credit Suisse Group Reiterates "Buy" Rating for Acceleron Pharma (XLRN) www.americanbankingnews.com - March 2 at 9:56 PM
	Acceleron Pharma Inc (XLRN) Expected to Post Q1 2018 Earnings of ($0.62) Per Share www.americanbankingnews.com - March 2 at 9:10 AM
	Research Analysts Set Expectations for Acceleron Pharma Inc's Q1 2018 Earnings (XLRN) www.americanbankingnews.com - March 2 at 9:10 AM
	Citigroup Increases Acceleron Pharma (XLRN) Price Target to $63.00 www.americanbankingnews.com - March 1 at 5:05 PM
	Acceleron Pharma Inc (XLRN) Forecasted to Earn FY2022 Earnings of ($0.07) Per Share www.americanbankingnews.com - March 1 at 4:08 PM
	Piper Jaffray Companies Boosts Acceleron Pharma (XLRN) Price Target to $53.00 www.americanbankingnews.com - February 28 at 4:44 PM
	Acceleron Pharma's (XLRN) Buy Rating Reiterated at HC Wainwright www.americanbankingnews.com - February 28 at 4:44 PM
	Acceleron Pharma (XLRN) Given New $54.00 Price Target at Barclays www.americanbankingnews.com - February 28 at 1:40 PM
	Acceleron Pharma (XLRN) Issues Quarterly Earnings Results, Misses Estimates By $0.02 EPS www.americanbankingnews.com - February 27 at 10:32 PM
	Acceleron Pharma Inc to Host Earnings Call finance.yahoo.com - February 27 at 5:55 PM
	Acceleron Reports Fourth Quarter and Full Year 2017 Operating and Financial Results finance.yahoo.com - February 27 at 5:55 PM
	Hudson Bay Capital Management LP Reduces Position in Acceleron Pharma Inc (XLRN) www.americanbankingnews.com - February 27 at 2:58 PM
	Acceleron Pharma (XLRN) Rating Increased to Overweight at JPMorgan Chase & Co. www.americanbankingnews.com - February 26 at 8:46 PM
	Carillon Tower Advisers Inc. Acquires Shares of 942,844 Acceleron Pharma Inc (XLRN) www.americanbankingnews.com - February 26 at 12:18 PM
	Acceleron Pharma Inc (XLRN) Expected to Announce Quarterly Sales of $3.39 Million www.americanbankingnews.com - February 26 at 4:38 AM
	Brown Advisory Inc. Grows Holdings in Acceleron Pharma Inc (XLRN) www.americanbankingnews.com - February 25 at 4:36 AM
	Zacks: Analysts Expect Acceleron Pharma Inc (XLRN) to Announce -$0.60 Earnings Per Share www.americanbankingnews.com - February 24 at 3:38 PM
	Citadel Advisors LLC Decreases Holdings in Acceleron Pharma Inc (XLRN) www.americanbankingnews.com - February 24 at 2:21 PM
	Acceleron Pharma (XLRN) Scheduled to Post Earnings on Tuesday www.americanbankingnews.com - February 20 at 3:46 AM
	Acceleron Pharma (XLRN) Rating Increased to Buy at BidaskClub www.americanbankingnews.com - February 17 at 9:54 PM
	Acceleron Pharma Inc (XLRN) Receives Average Recommendation of "Hold" from Brokerages www.americanbankingnews.com - February 14 at 11:48 AM
	Acceleron Announces Appointment of Chief Commercial Officer finance.yahoo.com - February 9 at 9:49 AM
	-$0.60 EPS Expected for Acceleron Pharma Inc (XLRN) This Quarter www.americanbankingnews.com - February 7 at 11:42 PM
	Acceleron to Present at the Leerink Partners 7th Annual Global Healthcare Conference finance.yahoo.com - January 31 at 9:37 AM
	Brokerages Anticipate Acceleron Pharma Inc (XLRN) Will Announce Quarterly Sales of $3.39 Million www.americanbankingnews.com - January 23 at 5:54 AM

Acceleron Pharma (NASDAQ:XLRN) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Acceleron Pharma (NASDAQ:XLRN) Income Statement, Balance Sheet and Cash Flow Statement

Acceleron Pharma (NASDAQ XLRN) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff